Abstract

ObjectiveThe Neonatal Adverse Event Severity Scale (NAESS) was developed to improve scoring of neonatal adverse events (AEs) and accelerate neonatal drug development. This is the first validation study of the novel tool.Study designRetrospective validation study assessing the inter-rater reliability (IRR) of the NAESS. Reviewers used real-world AE data from a neonatal trial. Intra-class correlation (ICC) statistical analysis was performed.ResultSixty AEs were randomly assigned to twelve reviewers for a total of 240 severity scores. Generic and AE-specific NAESS tables were assessed. The ICC was 0.63 (95% confidence interval 0.51 to 0.73). Percent variation due to reviewer and residual error was 0.03 and 0.34, respectively.ConclusionIn this first study of the NAESS tool, an ICC of 0.63 indicates moderate reliability. Results highlight the need for improved data collection on neonatal AE forms, augmented training on the NAESS tool, and will inform the prospective validation studies.

Highlights

  • Adverse event (AE) severity scoring is an essential component of all therapeutic intervention trials

  • We believe this response indicates that the reviewer has held jobs

  • An AE is defined by the Food

Read more

Summary

Introduction

Adverse event (AE) severity scoring is an essential component of all therapeutic intervention trials. Events are classified as serious (SAE) if they result in: inpatient hospitalization, prolongation of hospital course, a life-threatening occurrence, or death. The recognition and classification of AEs is challenging in neonates, those receiving intensive care who are most likely to be involved in clinical trials. Hospitalized neonates can have very complex physiology with multi-organ system dysfunction and many AEs. The unique types of neonatal AEs do not mirror the symptom classification in adults and children. Each pharmaceutical company and clinical research organization use their own approach and interpretation of neonatal AEs, making safety results from different studies difficult to compare. To study and ensure safety of a drug in neonates, investigators need a tool for improvement and standardization of neonatal AE collection and severity classification

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call